Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772755 · ClinicalTrials.gov registry record · NA
Presyncope (Syncope) Prevention Study
A NA study of Syncope, Vasovagal, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 338
- Enrollment target
- 2
- Study locations
NCT04772755: Completed NA study of Syncope, Vasovagal, sponsored by Duke University.
NCT04772755 is a NA study of Syncope, Vasovagal that has completed, run by Duke University. The registered enrollment target is 338 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04772755, a NA study of Syncope, Vasovagal, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 338 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study was a prospective, randomized clinical trial that was conducted in adolescents (10 through 14 years of age) receiving at least one recommended intramuscularly administered vaccine to evaluate the efficacy and acceptability of using two different, simultaneously administered interventions that might prevent post-vaccination presyncope, and by extension syncope. The two interventions evaluated together were Buzzy®, which is a medical device designed to reduce vaccination pain, and an electronic game. The investigators evaluated both interventions when administered simultaneously (Buzzy® and electronic game). The investigators enrolled approximately 340 subjects into this study. Eligible adolescents were randomized (1:1) to either the intervention or control group: 1) intervention (Buzzy® and electronic game); or 2) control (usual care) to assess for acceptability and efficacy. Detailed data were collected and described from study participants including demographics, medical history, baseline generalized and state anxiety, and needle phobia. Participants were observed for 20 minutes following receipt of vaccines and reassessed for post-vaccination state anxiety, immediate and subsequent post-vaccination pain (within 1 minute and at 10 minutes), and the occurrence of witnessed syncope or presyncope, and presyncopal symptoms as rated by the modified Blood Donation Reactions Inventory (BDRI). Participants were asked to assess their acceptability of the intervention.
Primary Outcome
Subjects were asked to complete a presyncope symptoms assessment (Modified BDRI: Blood Donations Reactions Inventory) at 20 minutes post vaccination. The number of adolescents with presyncope or syncope as determined by the modified BRDR or witnessed presyncope or syncope.
Conditions Studied
Interventions
- DEVICE Buzzy® and Electronic Game
Study Locations (2)
Georgia
- Centers for Disease Control and Prevention - Atlanta
North Carolina
- Duke University - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2022-06-15 |
| Phase | NA |
What the finished NCT04772755 record still lists
NCT04772755 is an interventional study that assigns participants to a tested intervention. The registered 338 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Syncope, Vasovagal appearing as the primary indexed condition, and to 1 intervention - of which Buzzy® and Electronic Game is the first listed.
NCT04772755 reports a single indexed study location in Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04772755 about?
NCT04772755 is a clinical study titled "Presyncope (Syncope) Prevention Study". This study was a prospective, randomized clinical trial that was conducted in adolescents (10 through 14 years of age) receiving at least one recommended intramuscularly administered vaccine to evaluate the efficacy and acceptability of using two different, simultaneously administered interventions ...
What is the current status of trial NCT04772755?
This trial is currently completed. It is a NA study. The enrollment target is 338 participants. The study started on 2021-03-10. Estimated completion is 2022-06-15.
What conditions does trial NCT04772755 study?
This clinical trial studies the following conditions: Syncope, Vasovagal.
What interventions are being tested in trial NCT04772755?
The interventions under investigation include: Buzzy® and Electronic Game (DEVICE).
Who is sponsoring clinical trial NCT04772755?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04772755 being conducted?
This trial has 2 study locations across Georgia, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Syncope, Vasovagal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04772755's enrollment target sits among peer trials
338 305th of 2000 higher than 1,696 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT04176172 · 340 participants · Phase 3
Optimizing Tobacco Use Treatment for PLWHA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI